Breaking News From Pharma & Bio Ingredients
OncoGenex Initiates Phase II Clinical Trial of OGX-011 in Cancer
Posted on 2005-10-25 17:09:00
OncoGenex Technologies Inc. has treated the first patient in a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with advanced breast cancer. OGX-011 is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anti-cancer treatments. This clinical trial is designed to assess the safety and efficacy of OGX-011 in combination with docetaxel in women with metastatic or locally advanced breast cancer. OncoGenex is developing OGX-011 in collaboration with Isis PharmaceuticalsInc.
Increased clusterin expression protects cancer cells from the cytotoxic effects of chemotherapy, leading to treatment resistance. By blocking the production of clusterin, OGX-011 may improve the effectiveness of existing chemotherapies. The primary objective of this study is to assess the objective response rates (reduction in tumor size) when OGX-011 is combined with docetaxel in patients with metastatic or locally recurrent breast cancer. Secondary endpoints include estimation of time to disease progression, overall survival and the effect of OGX-011 on serum clusterin.
Subscribe via RSS
